Does denosumab improve low BMD in postmenopausal women?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 11, 2006, Pages 600-601

  Favus, Murray J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; DENOSUMAB; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; BODY MASS; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; HIP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NOTE; OUTCOME ASSESSMENT; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33750619757     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0328     Document Type: Note

References (5)

1. Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338: 736-746
2. Bone HG et al. (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199
3. Tashjian AH Jr et al. (2006) Teriparatide [human PTH (1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21: 354-365
4. Boyle WJ et al. (2003) Osteoclast differentiation and activation. Nature 423: 337-342
5. Kostenuik PJ (2005) Osteoprotegrin and RANKL regulate bone resorption, density, geometry, and strength. Curr Opin Pharmacol 5: 618-625